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ABSTRACT
Background: Cognitive impairment is recognised as a significant clinical issue in Multiple Sclerosis (MS). It can occur at any 
stage of the disease, affecting quality of life, occupational activity, and adherence to therapy. This makes the availability of a va-
lidated assessment tool for detecting and monitoring cognitive dysfunction in multiple sclerosis essential. 
The Brief International Cognitive Assessment for Multiple Sclerosis is a practical and simple means of administering a battery of 
three neuropsychological tests, and does not require any formal neuropsychological training.
Objective: To establish the validity of BICAMS in the Polish MS population; to assess the correlations of cognitive status with 
demographic and clinical factors, including affective symptoms and fatigue.
Methods: BICAMS was administered to 61 MS patients and 61 HC subjects. Examination of 20 participants with MS was repea-
ted after one to three weeks to assess test-retest reliability. The patients with MS and HC subjects also completed the Hospital 
Anxiety and Depression Scale (HADS) and Modified Fatigue Impact Scale (MFIS).
Results: The MS group performed worse than the HC group in all three BICAMS components, obtaining the following values 
respectively: 51.7 and 56.1 (p = 0.02) for CVLT, 25 and 28 (p = 0.03) for BVMT-R, and 48.8 and 57.2 (p < 0.001) for SDMT. All BICAMS 
tests had very significant correlations in test-retest reliability (r = 0.83, p < 0.001 for CVLT; r = 0.84, p < 0.001 for BVMTR; r = 0.9, 
p < 0.001 for SDMT). 34% of MS patients presented cognitive dysfunction based on the criterion of one or more test scores be-
low the 5th percentile value of the HC group. Significant anxiety and depressive symptoms were reported by 31.1% and 18.0% 
of MS patients. 31.1% of PwMS reported significant fatigue. BICAMS test results were not associated with HADS or MFIS scores.
Conclusions: The Polish version of BICAMS is a valid and reliable tool for the assessment of cognitive impairment in patients 
with MS. 
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Introduction
Multiple Sclerosis (MS) is a chronic, inflammatory, auto-
immune, and neurodegenerative disease of the central nervous 
system (CNS), characterised by the presence of demyelinating 
lesions disseminated in space and time. It occurs primarily in 
young adults. MS is a heterogeneous disease with differentiated 
clinical courses [1]. MS leads to a wide range of symptoms. 
Cognitive impairment (CI) is one of the most common clin-
ical signs, occurring in 43–70% of PwMS (patients with MS) 
[2–3]. CI has a negative influence on quality of life, resulting in 
occupational disability, as well as restrictions on participating 
in social activities and personal relationships [4].
Cognitive deficits occur at all stages of the disease and 
clinical courses. Patients with radiologically isolated syndrome 
(RIS) demonstrate signs of cognitive impairment. 18–57% of 
patients have cognitive impairments after clinically isolated 
syndrome (CIS). 40% of patients with newly diagnosed MS 
have cognitive deficits [5–6]. The presence of CI in patients 
with CIS and RIS is associated with an increased risk of con-
version to MS [7], and cognitive impairment at MS diagnosis is 
associated with a faster accumulation of physical disability [8]. 
The early diagnosis of cognitive dysfunction is therefore 
highly significant. In some patients CI may be the predominant, 
or even exclusive, sign in the clinical manifestation of MS [9].
Cognitive impairment is the most marked in secondary 
progressive multiple sclerosis (SPMS) and primary progressive 
multiple sclerosis (PPMS), with typically a more severe course 
in SPMS. This may be because of a longer disease duration in 
SPMS [10]. However, cognitive deterioration in PwMS is less 
severe than that noted in dementing neurological disorders 
such as Alzheimer’s Disease. Cognitive processes in PwMS are 
often selectively affected. The most affected domains include 
information processing speed, attention, executive function, 
memory, and visuospatial abilities [3]. 
The relationship of cognitive deterioration to affective 
symptoms, as well as to fatigue, is complex. Mood disorders 
are common in PwMS. The most common is depression, which 
affects up to 50% of patients [11], while anxiety affects up to 
40% of PwMS [12]. Patients with affective symptoms more 
often report cognitive disturbances but may not demonstrate 
objective cognitive impairment [13]. Subjective cognitive 
dysfunction is more highly correlated with depressive symp-
toms than with objective cognitive deterioration [14–15]. An 
association between CI and depression is evident in patients 
with severe symptoms of depression. However, this relation 
is not unidirectional [16]. The association between anxiety 
and CI is less well understood. However, some studies have 
indicated that anxiety may also impact upon cognitive perfor-
mance, including information processing speed and executive 
function [17].
Fatigue is very common in PwMS, affecting up to 83% of 
individuals [18]. A correlation between fatigue and cognitive 
performance has been noted in some studies, especially in 
tasks demanding attention [19]. However, most studies have 
reported a lack of independent association between fatigue 
and cognitive performance [15, 20]. 
The poorly understood interrelations between cognitive 
dysfunction, affective symptoms, and fatigue complicate cog-
nitive assessment in PwMS. Both an assessment of depressive 
symptoms and of fatigue should be included during cognitive 
function examination [13–14].
As cognitive dysfunction in MS can be focal and mild, 
a precisely targeted approach in neuropsychological as-
sessment is necessary. Neuropsychological examination 
allows the detection of subtle cognitive disturbances, but 
has some limitations. There are resource implications for 
cognitive assessment. Various batteries of neuropsycho-
logical tests are recommended for PwMS. The most used 
are the Brief Repeatable Battery of Neuropsychological test 
(BRB-N) [21] and the Minimal Assessment of Cognitive 
Function in MS (MACFIMS) [22]. These batteries are 
time-consuming (administration takes 45 and 90 minutes 
respectively), and expensive, and need to be administered 
by specialised staff. 
In 2012, an expert panel recommended the Brief Inter-
national Cognitive Assessment in Multiple Sclerosis (BI-
CAMS) [23], which is relatively short, simple to administer, 
and does not require specialised staff. This set consists of 
three tools considered sensitive in identifying cognitive 
dysfunction in PwMS including the Rao adaptation [21] of 
the Symbol Digit Modalities Test (SDMT) [24], the initial 
learning trials of the second edition of the California Verbal 
Learning Test (CVLT-II) [25] and the initial learning trials 
of the revised Brief Visuospatial Memory Test (BVMT-R) 
[26]. International standards for BICAMS validation have 
been developed to facilitate validation and use in many 
countries [27].
Objectives
The aims of this study were to:
1. Establish the validity of BICAMS in the Polish MS pop-
ulation
2. Assess the cognitive status of Polish PwMS using BICAMS 
3. Assess the correlations of cognitive status with demo-




A total of 61 patients aged 18 or over with Multiple Scle-
rosis with a diagnosis based on the revised McDonald criteria 
[28], were included in the study. Patients were treated at the 
Department of Neurology and Clinical Neuroimmunology 
of the Regional Specialist Hospital in Grudziadz, Poland. 
Patients were recruited cross-sectionally, and no selection for 
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RRMS — relapsing-remitting multiple sclerosis, SPMS — secondary progressive multiple sclerosis, 
PPMS — primary progressive multiple sclerosis, EDSS — Expanded Disability Status Scale
cognitive impairment was performed before enrollment. The 
first language of all patients was Polish.
Exclusion criteria were: 
 — evidence of other neurological, psychiatric or systemic 
disease affecting cognitive function
 — taking medications affecting cognitive function
 — alcohol or drug abuse (current or past)
 — motor, sensory, vision or hearing dysfunction, which could 
influence the test’s performance
 — MS relapse or glucocorticosteroid treatment within the 
last four weeks.
61 healthy volunteers with no evidence of neurological, 
psychiatric, or systemic diseases affecting cognitive function 
were also assessed. The first language of all subjects was Polish.
The demographic characteristics of the groups are set out 
in Table 1. 
The median disease duration in the MS group was 7 years 
(3–13). The median Expanded Disability Status Scale (EDSS) 
was 3.5 (2–4.5). There were 45 patients with RRMS, 12 patients 
with SPMS, and four patients with PPMS. Table 2 sets out the 
demographic and clinical characteristics of PwMS depending 
on the course of the disease.
Procedures
This study was approved by the Bioethical Committee at 
the Regional Chamber of Physicians and Dentists in Bydgo-
szcz, Poland (No 39/2017, 19 September 2017). Procedures 
were performed according to international standards for 
validation [27]. After informed consent was obtained, a de-
mographic and clinical interview was performed, and subjects 
completed two self-administered questionnaires: Hospital 
Anxiety and Depression Scale (HADS) and Modified Fatigue 
Impact Scale (MFIS). Then the neuropsychological tests of the 
BICAMS battery were administered in this order: the Symbol 
Digit Modalities Test (SDMT, oral version), the California Ver-
bal Learning Test (CVLT), and the Brief Visuospatial Memory 
Test (BVMT-R). Finally, a neurological examination with EDSS 
assessment was performed by an experienced neurologist. All 
subjects were examined by the same psychologist and neurolo-
gist. The examination of 20 participants with MS was repeated 
after one to three weeks to assess test-retest reliability. All tests 
included in the BICAMS battery were repeated.
The Symbol Digit Modalities Test [24] measures informa-
tion processing speed. The SDMT is composed of nine symbols 
each in association with a single digit from 1 to 9. These pairs are 
explained at the top of the sheet as a key. The working area of the 
page contains a random sequence of these symbols. In the oral 
version the subjects have to say the correct digits as quickly as 
possible. They are scored on how many they get right in 90 sec. The 
instruction of administration was translated into the Polish lan-
guage. No other adaptation (linguistic or cultural) was required.
The California Verbal Learning Test-II [25] is a tool for 
measuring verbal memory and learning. The CVLT-II is 
composed of a list of 16 words in four semantic categories 
that the subject must learn. During administration, the ex-
aminer reads the list aloud at the approximate speed of one 
word per second. The subject listens to the complete list and 
is then asked to repeat back as many as possible, in any order, 
which the examiner records on paper. There is no time limit 
for this test. The procedure is repeated five times. The score is 
composed of the total number of words recorded across the 
five trials. In this study, the Polish adaptation of CVLT [29] 
was used. The Polish adaptation of CVLT contains the same 
number of words and number of trials as CVLT-II, and the 
words are culturally adapted for the Polish population.
The Brief Visuospatial Memory Test – Revised [26] is a test 
to evaluate visual memory and learning. The BVMT-R consist 
of six abstract figures on the sheet. This group of figures is 
shown to the subjects for 10 seconds. After this time, the page 
is removed and they are asked to draw as many figures as they 
can remember in the given order on a blank page. Each design 
is scored from zero to two points, based on accuracy and lo-
cation criteria. This is repeated three times. The total score is 
the sum of all three trials. The instruction of administration 
was translated into the Polish language. No other adaptation 
(linguistic or cultural) was required.
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Depression and anxiety were measured using the Hospi-
tal Anxiety and Depression Scale HADS) [30]. The HADS is 
a quick self-reported questionnaire containing 14 items, seven 
questions testing anxiety (HADS-A) and seven testing depres-
sion (HADS-D). Each item is rated from 0 to 3, which gives 
a possible range of scores from 0 (no symptoms) to 21 (most 
severe symptoms) for each subscale. Scores below 8 are normal. 
The HADS has been validated in MS [31]. The Polish version 
of the HADS [32] was used in this study.
The Polish version of the Modified Fatigue Impact Scale 
(MFIS) was used to measure fatigue [33]. The MFIS is a modi-
fied form of the Fatigue Impact Scale [34]. The MFIS contains 
21 items, 10 questions relating to mental fatigue, and 11 ques-
tions relating to physical and social fatigue. Each item is rated 
on a scale from 0 (never) to 4 (almost always). The scoring 
ranges between 0 and 84, with a high score reflecting a greater 
impact. A cut-off value of 38 has been used to discriminate 
fatigued from non-fatigued patients. 
Statistical analysis
Statistical analysis was performed using licensed software 
(Statistica 13.3, StatSoft). The statistical significance value was 
set at p < 0.05. Normal distribution of data was verified using 
the Shapiro-Wilk test. The mean (with standard deviation) was 
used as a measure of central tendency for data with normal 
distribution. Otherwise, the median (with 25 and 75 percen-
tile) was presented. The comparison between two groups for 
continuous variables was performed using:
 — t-test for independent variables - for variables with normal 
distribution and homogeneous variance in the groups; the 
homogeneity of variance was tested using Levene’s test,
 — t-test for independent variables with Welch’s correction for 
variables with normal distribution but unequal variances 
in the groups,
 — Mann-Whitney U test - for variables not meeting the 
assumption of normality.
The comparison between more than two groups for con-
tinuous variables was performed using one-way ANOVA with 
Tukey’s post hoc analysis where it was applicable: otherwise 
Kruskal-Wallis test was performed. The chi-square test was 
used to compare two groups for categorial variables. To assess 
correlation between two variables parametric test (Pearson’s 
correlation) or nonparametric test (Spearman rank correlation) 
was used depending on the character of a variable’s distribution. 
Correlation of BICAMS test-retest scores was evaluated by the 
Pearson correlation in accordance with the recommendations. 
In the analysis regarding more than one predictor of indepen-
dent variable, a multiple regression model was applied. 
Results
MS patients performed significantly worse on all three tests 
included in BICAMS compared to healthy subjects (Tab. 3). 






























Mann-Whitney U Test was used to assess the differences between the groups for BVMTR, T-Test was 
used for CVLT and SDMT. MS — multiple sclerosis, HC — healthy control, CVLT — California Verbal 
Learning Test, BVMTR — Brief Visuospatial Memory Test-Revised, SDMT — Symbol Digit Modalities 
Test, significant differences (p < 0.05) marked in bold
Effect sizes (Cohen’s d) were: 0.43 for CVLT, 0.46 for BVMT-R 
and 0.77 for SDMT.
Regarding test-retest reliability, all BICAMS tests produced 
significant correlations (r = 0.83 for CVLT, p < 0.001; r = 0.84, 
p < 0.001 for BVMTR; r = 0.9, p < 0.001 for SDMT).
Table 4 presents the results of the self-administered ques-
tionnaires (HADS and MFIS). The depression and anxiety 
subscales of the HADS were analysed separately. Significant 
anxiety symptoms were reported by 19 MS patients (31.1%) 
and 15 healthy subjects (24.6%). Significant depressive symp-
toms were reported by 11 MS patients (18%) and five healthy 
volunteers (8.2%). Using a cut-off point of 38 for the MFIS, 
19 MS patients (31.1%) and eight HC subjects (13.1%) reported 
significant fatigue. MFIS scores and subscale for cognitive 
aspect of fatigue were considered. Significant differences be-
tween the MS and HC groups were noted regarding the MFIS 
total score and MFIS — cognitive functioning. There was no 
difference in the case of the HADS (neither in depression nor 
anxiety symptoms). 
In the MS group, we found correlations between age and 
both BVMT-R and SDMT (R = -0.26, p = 0.04; R = -0.28, 
p = 0.03 respectively), as well as between education and BI-
CAMS tests (CVLT R = 0.42, p < 0.001, BVMT-R R = 0.5, p < 
0.001, SDMT R = 0.36, p = 0.005). Similarly, associations were 


































Mann-Whitney U Test was used to assess the differences between the groups, MS — multiple 
sclerosis, HC — healthy control, HADS-A — anxiety subscale of Hospital Anxiety and Depression 
Scale, HADS-D — depression subscale of Hospital Anxiety and Depression Scale, MFIS — Modified 
Fatigue Impact Scale, significant differences (p < 0.05) marked in bold
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RRMS — relapsing-remitting multiple sclerosis, SPMS — secondary progressive multiple sclerosis, 
HC — healthy control, CVLT — California Verbal Learning Test, BVMTR — Brief Visuospatial Memory 
Test-Revised, SDMT — Symbol Digit Modalities Test
Table 7. Cognitive impairment in MS patients according to the 5th percen-
tile values of HC group
5th percentile value 
of HC
Number (%) of MS 
patients with lower 
score
CVLT 41 8 (13%)
BVMTR 18 12 (20%)
SDMT 40 15 (25%)
HC — healthy control, MS — multiple sclerosis, CVLT — California Verbal Learning Test, BVMTR — 
Brief Visuospatial Memory Test-Revised, SDMT — Symbol Digit Modalities Test
Table 6. Associations between clinical factors and BICAMS scores — multiple regression analysis
CVLT BVMTR SDMT
Standardised B p Standardised B p Standardised B p
Age 0.003 0.98 -0.20 0.13 -0.06 0.65
Education 0.35 0.006 0.42 < 0.001 0.17 0.13
EDSS -0.14 0.34 -0.05 0.71 -0.51 < 0.001
Duration of the disease -0.17 0.23 -0.12 0.36 -0.03 0.82
CVLT — California Verbal Learning Test, BVMTR — Brief Visuospatial Memory Test-Revised, SDMT — Symbol Digit Modalities Test, EDSS — Expanded Disability Status Scale, significant correlations (p < 0.05) 
marked in bold
noticed in the HC group in the case of education (R = 0.47, 
p < 0.001, R = 0.27, p = 0.04, R = 0.44, p < 0.001 respective-
ly). However, in the HC group, age was correlated only with 
SDMT (R = -0.35, p = 0.005). No association of BICAMS 
to gender was observed. Unemployed PwMS performed 
worse than employed subjects on the CVLT (unemployed 
42.7, SD 9.9; employed 53.5, SD 10.3; p = 0.003) as well as 
on the SDMT (unemployed 41.9, SD 12.4; employed 50.2, 
SD 11.7; p = 0.04). There was no relationship of employment 
status to BVMT-R.
When considering the differences of cognitive perfor-
mance associated with the clinical courses of MS, we excluded 
the PPMS group because of the small number of patients. 
Significant differences in performance on all three tests were 
observed between the SPMS and HC groups (p = 0.02 for 
CVLT, p = 0.02 for BVM-TR, p < 0.001 for SDMT). Moreover, 
a significant difference between SPMS and RRMS for SDMT 
(p = 0.01) was also found (Tab. 5).
There was no significant association of the BICAMS test 
with either HADS or MFIS scores.
Patients with higher EDSS performed worse on CVLT, 
BVMT-R and SDMT (R = -0.31, p = 0.01; R = -0.27, p = 0.04; 
R = -0.58, p < 0.001 respectively). BVMT-R and SDMT results 
were also negatively correlated with duration of the disease (R 
= -0.26, p = 0.04; R = -0.32, p = 0.01).
We also analysed BICAMS scores within the MS group 
in a regression model including age, education, EDSS and 
duration of the disease (Tab. 6). This analysis revealed that 
EDSS was the only predictor of SDMT, whereas education 
was a predictor of BVMTR and CVLT scores.
We identified the 5th percentile value in the HC group for 
each component of BICAMS to estimate how many MS pa-
tients underperformed (Tab. 7). We identified 21 MS patients 
(34%) presenting with cognitive dysfunction based on the cri-
terion of one or more test result below the 5th percentile value 
of the HC group. 11 MS patients (18%) performed poorly on 
only one BICAMS test, six patients (10%) performed poorly 
on two BICAMS components, while four MS subjects (7%) 
demonstrated impairment on all three tests.
Discussion
Evidence regarding the prevalence of CI in MS has in-
creased significantly in recent years. Results of studies on 
CI in MS have raised awareness of the seriousness of this 
problem, particularly in relation to its negative impact on the 
daily lives of MS patients. CI results in a limitation of social 
and interpersonal activity, as well as of the ability to work and/
or study and of treatment adherence and rehabilitation [23]. 
Following these findings, some tools aimed at CI assessment in 
MS patients were developed, but a comprehensive clinical cognitive 
assessment requires additional expertise, which is not available in 
many MS centres, particularly smaller ones. This resulted in the 
need for a short cognitive testing battery which captures cognitive 
performance of MS patients and can be quickly and efficiently 
applied in everyday practice by neurologists. An expert consensus 
committee of neurologists and neuropsychologists developed 
the BICAMS battery, offering adequate reliability, sensitivity, 
specificity, and repeatability [23]. Based on validation standards 
recommended by an expert panel [27], BICAMS has been suc-
cessfully validated, and it is currently used in many countries [35]. 
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We found a significant difference in scores between PwMS 
and HC. This was most pronounced for the SDMT, where 
scores for MS patients were substantially lower compared 
to HC. However, our findings are consistent with the results 
of earlier studies [36–39]. When using a criterion of at least 
one test below the normal HC range, we found cognitive 
deficits in 34% of MS patients. We also demonstrated a very 
strong correlation in test-retest reliability assessment, which 
is also concordant with earlier data. In our study, there was 
a significant difference in employment levels between the 
MS and HC groups. This is a well-established phenomenon 
in previous BICAMS validation studies, and it is known that 
unemployment is high for people with MS, even with low 
EDSS, both in Poland [40] and across Europe [41]. The much 
higher unemployment rate of the MS group reflects the reality 
of MS, and we do not consider this to be a statistical anomaly. 
However, the prevalence of CI was lower in our population 
than in other recent studies [36–38, 42], which is probably 
a result of the short duration of the disease in the majority of 
our RRMS patients. A recent BICAMS validation with a short 
mean disease duration reported similar impairment levels [39]. 
This can be confirmed by the effect of the disease phenotype on 
test results, with RRMS patients (with the shortest duration of 
the disease) receiving the best scores, and SPMS patients (with 
the longest duration of the disease) the worst. The difference 
between RRMS and SPMS was significant for SDMT. Scores 
of SPMS patients and HC differed significantly for all three 
tests. Our findings confirm earlier findings describing different 
patterns of CI in different MS phenotypes and in relation to 
the duration of the disease [5, 10].
Age-related cognitive decline has been well documented 
in the scientific literature, in terms of information processing 
speed, verbal memory and visuospatial abilities [43]. A neg-
ative correlation of test scores in the BICAMS battery with 
age, both in HC and PwMS, is therefore to be expected. Our 
data has confirmed previous results regarding the correlation 
of age with SDMT and BVMT-R in PwMS and with SDMT 
in the HC group.
Education was associated with higher cognitive test scores, 
possibly as an indicator of cognitive reserve. We did not find 
a difference in years of education between HC and PwMS. 
A correlation of CVLT and SDMT with the level of education 
has been previously reported [29, 44]. The BVMT-R manual 
states that education does not influence performance [26], and 
in another normative study the level of education correlated 
only with CVLT performance [45]. In this study, we described 
the significant effect of the level of education on all BICAMS 
tests, both in MS patients and HC. Some previous data indi-
cates more severe cognitive decline in male PwMS compared 
to females [46], which can lead to even more pronounced 
differences between genders for tests in which male subjects 
routinely perform worse (e.g. CLVT). However, in our study, 
the BICAMS test results were not associated with gender. We 
found that CVLT was a strong predictor for occupational 
activity in PwMS, which is similar to the observation made in 
the Czech validation of BICAMS and MACFIMS scales [36]. 
But we also found a similar relationship for SDMT. 
Our study confirms earlier findings of a correlation of 
cognitive decline with motor disability, as assessed by EDSS, 
and the duration of the disease. Longer duration of the disease 
and a higher EDSS score have been significantly correlated 
with CI severity in MS patients [5]. Both those parameters are 
related, as EDSS scores strongly correlate with the duration of 
the disease. However, in our dataset we established EDSS as 
the strongest predictor of SDMT performance using a multiple 
regression model. In this model, we observed that education 
was the strongest predictor of CVLT and BVMTR, while the 
effect of EDSS and duration of the disease became insignifi-
cant for these BICAMS components. The protective effect of 
a high level of education on cognitive deterioration in patients 
with MS was noted in previous studies [47]. Moreover, CVLT 
performance is associated with education in healthy subjects. 
In this study, education also correlated with all the BICAMS 
components in the HC group. While our sample of MS patients 
had low mean EDSS level and relatively short duration of the 
disease, it is interesting that the variance accounted for by 
education exceeded that of both EDSS and duration of disease.
Previous validation and other studies using BICAMS have 
investigated the relation of clinical and demographic variables 
to BICAMS performance. Mood disorders were observed in 
the form of depression in 18% and 8.2%, and as anxiety in 
31.1% and 24.6% of MS patients and HC, respectively. The dif-
ference in prevalence between MS and HC was not significant. 
However, both prevalence and severity of depression were no-
tably lower in our group compared to earlier studies, in which 
clinically meaningful depression was observed in 30–50% of 
patients [11–12]. A link between depressive symptoms and 
verbal memory performance has been described [19] and the 
influence of depression on processing speed is also known [48], 
but in our study we found no correlation between the HADS 
depression subscale and BICAMS tests results. 
The association between the intensity of anxiety symptoms 
and cognitive impairment in MS patients is weaker than for 
depressive symptoms, as has been suggested previously [17]. 
We found no correlation between the intensity of anxiety 
symptoms and the extent of cognitive impairment. Data re-
garding the impact of affective symptoms on cognition is not 
uniform; the lack of such influence was described in a recent 
study [49], but the influence of other factors (such as EDSS, 
disease duration and fatigue) on cognitive performance was 
emphasised. 
As expected, fatigue was more prevalent in MS patients 
compared to controls, both when assessed by the overall MFIS 
and the MFIS-cognitive functioning subscale. Approximately 
30% of our MS patients reported significant symptoms of 
fatigue. An association between fatigue and cognitive im-
pairment has been shown in some studies, especially in tasks 
requiring prolonged attention [19]. This was confirmed by the 
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Hungarian validation work [37], where a strong correlation 
of fatigue with performance on all three BICAMS tests was 
observed. Nevertheless, a recent study on a large group of 
patients did not confirm the effect of fatigue on processing 
speed, attention, executive function, and memory [50], which 
is consistent with the results of our study. 
Conclusions
The Polish version of BICAMS is a sensitive, specific, and 
short battery of cognitive tests, allowing the assessment and 
monitoring of cognitive impairment in MS patients. 
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